Authors say disparities in LVAD use by race, sex likely driven by clinician decision-making
MONDAY, Aug. 1, 2022 (HealthDay News) — Disparities in left ventricular assist device (LVAD) use by race and sex exist among Medicare beneficiaries hospitalized for heart failure and are not explained by clinical characteristics or social determinants of health, according to a study published online July 27 in JAMA Network Open.
Thomas M. Cascino, M.D., from the University of Michigan in Ann Arbor, and colleagues assessed inequities in LVAD use and outcomes according to race and sex. The analysis included 12,310 Medicare beneficiaries admitted for heart failure from 2008 to 2014.
The researchers found that Black beneficiaries were 3.0 percent less likely to receive an LVAD than White beneficiaries, while women were 7.9 percent less likely to receive an LVAD than men. Reduced use was also associated with individual poverty and worse neighborhood deprivation (2.9 and 6.7 percent, respectively), although these measures did little to explain observed disparities. The racial disparity was primarily seen among patients with a low propensity score (propensity score <0.52). On average, one-year survival was similar by race and sex, but Black patients with a low propensity score experienced improved survival (7.2 percent).
“Inequity in LVAD access may have resulted from differences in clinician decision-making because of systemic racism and discrimination, implicit bias, or patient preference,” the authors write.
Two authors disclosed financial ties to the pharmaceutical industry.
Warning Symptoms, Clinical History Can Predict Sudden Cardiac Arrest
Hispanic Patients Face Delays in Frontotemporal Dementia Diagnosis
AI Can Accurately Detect Left Ventricular Dysfunction From Electrocardiograms
AHA: Consuming Up to 400 mg/Day of Caffeine Safe for Most Adults
Physical Activity Reduces Stroke, Mortality, Regardless of A-Fib
Long-Term Medication Adherence Tied to Lower Cardiovascular Event Rate in Type 2 Diabetes
High-Dose Omega-3 Linked to A-Fib Risk in Patients With High CVD Risk
Add-On Tirzepatide May Reduce MACE Risk in People With T2D, ASCVD